… inhibition, may not be sufficient in themselves as a guide to the anticancer effects of MEK
inhibition… influence the potential therapeutic outcomes of MEK inhibition in cancer patients: (1) …

… pathway in carcinogenesis and as a novel therapeutic oncogenic target. Particular attention
is paid to MEK inhibitors (MEKi) as promising therapeutic agents. We describe the clinical …

… MEK2, and RAF-addicted tumour cells are also MEK-addicted, MEK1 and MEK2 are also …
allosteric inhibitors. However, MEK1 and MEK2 are rarely mutated in cancer, so MEK inhibitors …

… Abstract: This paper reviews recent progress in the design and evaluation of MEK inhibitors
as cancer therapeutics. Activation of the Ras / Raf / MEK / MAP kinase pathway has been …

… MEK inhibitors, and the results obtained to date with MEK inhibitors in human cancer trials.
… combinations are likely and may show the true utility of MEK inhibitors in cancer treatment …

… -independent mechanisms it is expected that the clinical activity and toxicity profile of MEK
inhibitors will differ from that of RAF inhibitors. PD98059 and U0126 were the first selective …

… Herein, we review the MEK1/2 signalling pathway in the context of cancer therapy. We provide
a brief introduction to MEK1/2 signalling and its contribution to tumorigenesis. In addition, …

… MEK2) are under investigation; however, potential differences are not yet clearly relevant
in the development of MEK inhibitors for cancer therapy. Phosphorylated MAPK/ERK proteins …

… alternative possibility is that the MEK-ERK pathway may not … in developing MEK inhibitors
for cancer therapy. Recent … discuss strategies of using MEK inhibitors in cancer therapy. …

… current understanding of the role of MEK in cancer cell proliferation and the … MEK inhibitor
class, have been described. Future combinations of MEK inhibitors with other cancer therapy …